Skip to main content

Table 7 Overall response rate fluctuation in different studies of chemotherapy + bevacizumab

From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

Study

N (CT/BCT)*

CT ORR

BCT ORR

Risk Ratio

AVF0757 [11]

32/34

18.8%

32.4%

0.58

JO19907 [10]

59/121

33.9%

56.2%

0.60

AVAiL [12]

327/329

21.7%

34.7%

0.63

E4599 [9]

392/381

15.1%

34.9%

0.43

FDA’s meta-analysis [7]

810/865

19.3%

37.7%

0.53

BCD-021-2

NA/206

NA

34.6%

NA

  1. *N: ITT population; CT: chemotherapy; BCT: bevacizumab with chemotherapy; NA: not applicable